Indefinite Delivery Contract 75A50122D00008

Award Date 7/28/22
Last Date to Order 7/31/25
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Clinger Cohen Act
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Lovelace Biomedical Research Institute a single award indefinite delivery contract with a potential value of $100 million. The contract aims to procure biological animal model and medical countermeasure development services through flexible contracting solutions. Lovelace Biomedical will utilize its expertise to assist the agency in oversight of its Indefinite Delivery Indefinite...
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a single-award, indefinite delivery/indefinite quantity contract valued up to $100 million to Lovelace Biomedical Research Institute. Under this contract, Lovelace will establish and utilize animal models to support the development of medical countermeasures against radiological and nuclear threats. A $1.986 million cost-plus-fixed-fee delivery order was issued to Lovelace for...
The federal contract IDV award provides indefinite delivery of nonclinical biological services to the Department of Health and Human Services (HHS), specifically the Office of the Assistant Secretary for Preparedness and Response (ASPR). The purpose is to establish a network of Good Laboratory Practices (GLP) facilities capable of conducting animal testing and other analytical services to support the development of medical countermeasures against chemical, biological, radiological, and nuclear...
The Federal Supply Schedule contract GS07F6002R was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute, a not-for-profit contract research organization. This multiple award IDV provides a range of preclinical research services to federal agencies such as the NIH, NIAID, NCATS, BARDA, and Leidos. Through task orders under this contract, LBERI performs activities like efficacy testing of HIV therapeutics,...
This is a single-award indefinite delivery contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS), to Battelle Memorial Institute, a nonprofit research and development organization. The $90 million IDIQ contract, which runs through July 2025, is for the development of animal models and medical countermeasures related to chemical, biological, radiological, and nuclear threats. Under...
This indefinite delivery contract was awarded by the National Center for Advancing Translational Sciences (NCATS), part of the U.S. Department of Health and Human Services, to Lovelace Biomedical Research Institute, a not-for-profit contract research organization based in Albuquerque, New Mexico. The $17.89 million multiple-award contract, which runs through April 2025, is for contract research organization (CRO) support for NCATS' medicinal chemistry work focused on lead optimization. Under the...
This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $48.6 million multiple-award IDC has a 6-year ordering period from June 2024 to June 2030. The contract aims to procure safety evaluation and toxicology studies and related services to support drug development efforts at NCATS....
This indefinite delivery contract (IDC) was awarded by the Defense Health Agency (DHA), a defense agency, to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $2,500.00 firm-fixed-price delivery order is for military medical research and development services, with no set-aside designation. Lovelace Biomedical Research Institute provides pharmaceutical and biotechnology partners with a range of preclinical research services across the drug...
This federal Indefinite Delivery Contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Battelle Memorial Institute, a nonprofit research organization. The $100 million IDIQ contract, titled "BARDA Chem and RadNuc Animal Model 2015-2020", aims to develop human-relevant small animal models for studying the effects of chemical warfare agents and support...
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a component of the U.S. Department of Health and Human Services (HHS), to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The $45 million single-award IDC has a period of performance through July 31, 2025 and is for the development of animal models to evaluate the efficacy of medical countermeasures (MCMs)...

The Department of Health and Human Services (HHS) awarded an indefinite delivery/indefinite quantity (IDIQ) contract to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization, to provide nonclinical laboratory services for the development and testing of medical countermeasures against chemical threats. The $45 million, single-award IDIQ contract has a period of performance through July 2025.

The contract scope covers two groups of services: Group A for pulmonary agents, cyanide, opioids, and other chemical agents, and Group B for nerve agents and blister agents. Lovelace must demonstrate prior experience conducting Good Laboratory Practice (GLP) studies involving these threat agents and animal models that mimic human exposure and disease. The contract aims to support the Biomedical Advanced Research and Development Authority's (BARDA) mission to develop medical countermeasures for chemical, biological, radiological, and nuclear threats, as enabled by the Animal Rule regulatory pathway. Task orders will be issued to leverage Lovelace's expertise in areas such as respiratory and toxicology assessments, pharmacology studies, and product manufacturing to advance candidate treatments.

Generated 8/1/24, 9:15 AM